Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients

Breast Cancer Research and Treatment

Volumn 124, Issue 2, 2010, Pages 593-598

  Rizzo, Roberta ^a   Spaggiari, Federica ^b   Indelli, Monica ^b   Lelli, Giorgio ^b   Baricordi, Olavio R ^a   Rimessi, Paola ^a   Ferlini, Alessandra ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

ABCB1; Biomarkers; Breast cancer; CYP1B1; CYP2C8; Taxane

Indexed keywords

4 METHOXYESTRADIOL; ANTHRACYCLINE; CORTICOSTEROID; CYTOCHROME P450 1B1; CYTOCHROME P450 2C8; DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; DRUG HYPERSENSITIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NEUROTOXICITY; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK FACTOR; SENSORY NEUROPATHY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG HYPERSENSITIVITY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ODDS RATIO; P-GLYCOPROTEIN; PACLITAXEL; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME;

EID: 78649330294     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1034-5     Document Type: Article

References (28)

1. M Abal JM Andreu I Barasoain 2003 Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action Curr Cancer Drug Targets 3 193 203 1:CAS:528:DC%2BD3sXjvVektL8%3D 10.2174/1568009033481967 12769688 (Pubitemid 36565761)
2. M Markman 2003 Management of toxicities associated with the administration of taxanes Expert Opin Drug Saf 2 141 146 1:CAS:528: DC%2BD3sXis1yjsbw%3D 10.1517/14740338.2.2.141 12904114
3. H Steed MB Sawyer 2007 Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel Pharmacogenomics 8 803 815 1:CAS:528: DC%2BD2sXnvVertr4%3D 10.2217/14622416.8.7.803 17638515 (Pubitemid 47288979)
4. S Marsh 2006 Taxane pharmacogenetics Pers Med 3 33 43 1:CAS:528:DC%2BD28XlsFKitLo%3D 10.2217/17410541.3.1.33
5. JW Harris A Rahman BR Kim FP Guengerich JM Collins 1994 Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme Cancer Res 54 4026 4035 1:CAS:528: DyaK2cXlt1Cmsbc%3D 7913410
6. A Rahman KR Korzekwa J Grogan FJ Gonzalez JW Harris 1994 Selective biotransformation of taxol to 6 a-hydroxytaxol by human cytochrome P450 2C8 Cancer Res 54 5543 5546 1:CAS:528:DyaK2cXmvFWqtLg%3D 7923194
7. A Sparreboom J van Asperen U Mayer, et al. 1997 Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc Natl Acad Sci USA 94 2031 2035 1:CAS:528:DyaK2sXhslCjs7o%3D 10.1073/pnas.94.5.2031 9050899 (Pubitemid 27113956)
8. M Iscan T Klaavuniemi T Coban N Kapucuoglu O Pelkonen H Raunio 2001 Breast Cancer Res Treat 70 47 54 1:CAS:528:DC%2BD38XmtVKlsw%3D%3D 10.1023/A:1012526406741 11767004 (Pubitemid 33105102)
9. MC McFadyen ME Cruickshank ID Miller, et al. 2001 Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer Br J Cancer 85 242 246 1:CAS:528:DC%2BD3MXmtVKht78%3D 10.1054/bjoc.2001.1907 11461084 (Pubitemid 32695746)
10. N Bahadur JB Leathart E Mutch, et al. 2002 CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6a-hydroxylase activity in human liver microsomes Biochem Pharmacol 64 1579 1589 1:CAS:528: DC%2BD38XosFKls7o%3D 10.1016/S0006-2952(02)01354-0 12429347 (Pubitemid 35333419)
11. EB Daily CL Aquilante 2009 Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies Pharmacogenomics 9 1489 1510 10.2217/pgs.09.82
12. TM Sissung K Mross SM Steinberg, et al. 2006 Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia Eur J Cancer 42 2893 2896 1:CAS:528:DC%2BD28XhtFOjt7fK 10.1016/j.ejca.2006.06.017 16950614 (Pubitemid 44755257)
13. TM Bosch AD Huitema VD Doodeman R Jansen, et al. 2006 Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel Clin Cancer Res 12 5786 5793 1:CAS:528:DC%2BD28XhtVartbjM 10.1158/1078-0432.CCR-05-2649 17020985 (Pubitemid 44629610)
14. H Green P Soderkvist P Rosenberg G Horvath C Peterson 2006 MDR-1single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy Clin Cancer Res 12 854 859 1:CAS:528:DC%2BD28XhtFeiurc%3D 10.1158/1078-0432.CCR-05-0950 16467099 (Pubitemid 43259868)
15. S Marsh CR King HL McLeod J Paul G Gifford R Brown 2006 ABCB1 2677G > T/A genotype and paclitaxel pharmacogenetics in ovarian cancer Clin Cancer Res 12 4127 4129 1:CAS:528:DC%2BD28XmsVaks7Y%3D 10.1158/1078-0432.CCR-06-0461 16818714
16. C Marzolini E Paus T Buclin RB Kim 2004 Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 13 33 1:CAS:528:DC%2BD2cXntVKiuw%3D%3D 10.1016/j.clpt.2003.09.012 14749689 (Pubitemid 38130115)
17. S Marsh G Somlo X Li, et al. 2007 Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer Pharmacogenomics J 7 362 365 1:CAS:528:DC%2BD2sXhtVOrtLjJ 10.1038/sj.tpj.6500434 17224914 (Pubitemid 47484774)
18. S Marsh HL McLeod 2007 Pharmacogenetics and oncology treatment for breast cancer Expert Opin Pharmacother 8 119 127 1:CAS:528:DC%2BD2sXptFCisw%3D%3D 10.1517/14656566.8.2.119 17257083 (Pubitemid 46206615)
19. TM Sissung R Danesi DK Price, et al. 2008 Association of the CYP1B1 3 allele with survival in patients with prostate cancer receiving docetaxel Mol Cancer Ther 7 19 26 1:CAS:528:DC%2BD1cXmsVygsg%3D%3D 10.1158/1535-7163.MCT-07- 0557 18187806
20. Common Terminology Criteria for Adverse Events v3.0 (publish date 9 Aug 2006). http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf
21. S Marsh J Paul CR King G Gifford HL McLeod R Brown 2007 Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer J Clin Oncol 25 4528 4535 1:CAS:528:DC%2BD2sXht1yhsr7P 10.1200/JCO.2006.10.4752 17925548 (Pubitemid 350035308)
22. JG Liehr MJ Rocci 1996 4-Hydroxylation of estrogens as marker of human mammary tumors Proc Natl Acad Sci USA 93 3294 3296 1:CAS:528:DyaK28XisVWisLw%3D 10.1073/pnas.93.8.3294 8622931 (Pubitemid 26125612)
23. MCE McFayden HL McLeod FC Jackson WT Mel Vin J Doehmer GI Murray 2001 Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance Biochem Pharmacol 62 207 212 10.1016/S0006-2952(01)00643-8 (Pubitemid 32522940)
24. DN Li A Seidel MP Pritchard CR Wolf T Friedberg 2000 Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol Pharmacogenetics 10 343 353 1:CAS:528: DC%2BD3cXksFSqtr4%3D 10.1097/00008571-200006000-00008 10862525
25. B Bournique A Lemarie 2002 Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme Drug Metab Dispos 30 1149 1152 1:CAS:528:DC%2BD38XotFyktbc%3D 10.1124/dmd.30.11.1149 12386117 (Pubitemid 35265818)
26. MT Landi AW Bergen A Baccarelli, et al. 2005 CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy Toxicology 207 191 202 1:CAS:528:DC%2BD2cXhtVKksrrM 10.1016/j.tox.2004.08.021 15596250 (Pubitemid 39642835)
27. T Shimada J Watanabe K Kawajiri, et al. 1999 Catalytic properties of polymorphic human cytochrome P450 1B1 variants Carcinogenesis 20 1607 1613 1:CAS:528:DyaK1MXltlKnsrg%3D 10.1093/carcin/20.8.1607 10426814 (Pubitemid 29385452)
28. IH Hanna S Dawling N Roodi FP Guengerich FF Parl 2000 Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity Cancer Res 60 3440 3444 1:CAS:528:DC%2BD3cXkvFChs7s%3D 10910054